Pharmaceuticals New York City Page 2 - drug development medicines

Callisto Pharmaceuticals, Inc. (Callisto) is a biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), acute leukemia and gastrointestinal disorders and diseases. The ...

Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of plant based dietary supplements. During the year ended December 31, 2006, the products sold by the Company include Sinusol, Lo-Chol and ACA. During July 1999, the Company ...

SIGA Technologies, Inc. (SIGA) is a biotechnology company that discovers, develops and commercializes anti-infectives for serious infectious diseases. The major focus of the Company's developmental and commercialization activities is on products for use ...

Callisto Pharmaceuticals, Inc. (Callisto) is a biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), acute leukemia and gastrointestinal disorders and diseases. The ...

Callisto Pharmaceuticals, Inc. (Callisto) is a biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), acute leukemia and gastrointestinal disorders and diseases. The ...

BrainStorm (OTC BB: BCLI) is a company that is developing stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing adult stem cells taken from the patient's own bone marrow to ...

ACCESS Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and marketing novel therapeutics for cancer and related conditions. ACCESS has built a portfolio of proprietary anti-cancer product candidates through the in-licensing ...

Bioenvision's primary focus is the acquisition, development, distribution and marketing of compounds and technologies for the treatment of cancer. Bioenvision has a broad pipeline of products for the treatment of cancer, including: Evoltra(TM), Modrenal(R ...

We are a development stage company that was established to focus on the research and development of novel all-natural drugs for a better quality of life by using the best of traditional medicines from the Amazon region of South America and from nature ...

NexGenix is the leading biotechnology company in the field of neurofibromatosis and is designing innovative drugs for unmet medical needs, using our expertise to develop therapies for the treatment of NF1, NF2, other tumor-causing genetic disorders and ...

Sanofi-Synthelabo is a major global research-based pharmaceutical group with 33,000 employees in more than 100 countries. The company is headquartered is Paris, and listed in Paris (Euronext: SAN) and in New York (NYSE: SNY). With consolidated sales of ...

Sanofi-Synthelabo is a major global research-based pharmaceutical group with 33,000 employees in more than 100 countries. The company is headquartered is Paris, and listed in Paris (Euronext: SAN) and in New York (NYSE: SNY). With consolidated sales of ...

Sanofi is a French multi-national health care corporation dedicated to developing novel and innovative therapeutic agents for a wide range of clinical disorders. Xaliproden is an original Sanofi compound which exhibits neurotrophic and neuroprotective ...

Lescarden Inc. (Lescarden) is engaged in the research and development of biologic materials with a focus on wound healing, clinical skin care, osteoarthritis and cancer applications. Its product line is led by CATRIX Wound Dressing, a powder derived from ...

Manhattan Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing pharmaceutical therapies for underserved patient populations. The Company has four product candidates in development: Hedrin ...

Manhattan Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing pharmaceutical therapies for underserved patient populations. The Company has four product candidates in development: Hedrin ...

Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of plant based dietary supplements. During the year ended December 31, 2006, the products sold by the Company include Sinusol, Lo-Chol and ACA. During July 1999, the Company ...

Advanced Plant Pharmaceuticals, Inc. (APPI) focuses on the research and development of plant based dietary supplements. During the year ended December 31, 2006, the products sold by the Company include Sinusol, Lo-Chol and ACA. During July 1999, the Company ...

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biopharma company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily infectious diseases. Its vaccines ...

ZIOPHARM Oncology, Inc. (ZIOPHARM), incorporated in September 2003, is a development-stage biopharmaceutical company. The Company focuses on developing and commercializing a portfolio of in-licensed cancer drugs that address unmet medical needs. The Company ...

IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS,s product ...

Manhattan Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing pharmaceutical therapies for underserved patient populations. The Company has four product candidates in development: Hedrin ...

ZIOPHARM Oncology, Inc. (ZIOPHARM), incorporated in September 2003, is a development-stage biopharmaceutical company. The Company focuses on developing and commercializing a portfolio of in-licensed cancer drugs that address unmet medical needs. The Company ...

Manhattan Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing pharmaceutical therapies for underserved patient populations. The Company has four product candidates in development: Hedrin ...

Sanofi is a French multi-national health care corporation dedicated to developing novel and innovative therapeutic agents for a wide range of clinical disorders. Xaliproden is an original Sanofi compound which exhibits neurotrophic and neuroprotective ...